

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/777,008
		Filing Date	February 11, 2004
		First Named Inventor	Emil Martin
		Group Art Unit	1651 / 1655
		Examiner Name	
Sheet 1 of 2	Attorney Docket Number	2105-01001	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
12	AA	US-2002/0155166	10-24-2002	Choi et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
12	AB	Abrams, J., Beneficial actions of nitrates in cardiovascular disease. <i>Am J Cardiol</i> , 1996. 77(13): p. 31C-7C	
	AC	Deinum, G., et al., Binding of Nitric Oxide and Carbon Monoxide to Soluble Guanylate Cyclase as Observed with Resonance Raman Spectroscopy. (1996) <i>Biochemistry</i> 35 (5), 1540-7	
	AD	Do, Y.S., et al., In-Stent Restenosis Limitation With Stent-Based Controlled-Release Nitric Oxide: Initial Results in Rabbits. <i>Radiology</i> , 2004. 230(2): p. 377-82	
	AE	Evans, C.H., et al., Osteoarthritis gene therapy. <i>Gene Ther</i> , 2004. 11(4): p. 379-89	
	AF	Friebe, A., and Koesling, D., Mechanism of YC-1-Induced Activation of Soluble Guanylyl Cyclase. (1998) <i>Mol Pharmacol</i> 53 (1), 123-7	
	AG	Gallo, O., et al., Role of Nitric Oxide in Angiogenesis and Tumor Progression in Head and Neck Cancer. <i>J Nat'l Cancer Inst</i> , 1998. 90(8): p. 587-96	
	AH	Lee, Y. C., et al., Human Recombinant Soluble Guanylyl Cyclase: Expression, Purification, and Regulation. (2000) <i>Proc Nat'l Acad Sci USA</i> 97(20), 10763-8	

Examiner Signature	12 G. Tomen	Date Considered	7/24/06
--------------------	-------------	-----------------	---------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. Send To Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	2	Application Number	10/777,008
				Filing Date	February 11, 2004
				First Named Inventor	Emil Martin
				Group Art Unit	1651/655
				Examiner Name	
				Attorney Docket Number	2105-01001

Complete if Known**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RG	AI	Martin, E., et al., YC-I Activation of Human Soluble Guanylyl Cyclase has Both Heme Dependent and Heme Independent Components. <i>PNAS. Proc Nat'l Acad Sci USA</i> (Nov. 6, 2001) 98 (23), 12938-42	
	AJ	Okawa, H., et al., Preischemic Infusion of Alpha-Human a Trial Natriuretic Peptide Elicits Myoprotective Effects Against Ischemia Reperfusion in Isolated Rat Hearts. <i>Mol Cell Biochem</i> , 2003. 248(1-2): p. 171-7	
	AK	Sinnaeve, P., et al., Overexpression of a Constitutively Active Protein Kinase G Mutant Reduces Neointima Formation and In-Stent Restenosis. <i>Circulation</i> , 2002. 105(24): p. 2911-6	
	AL	Stasch, J. P., et al., Pharmacological actions of a Novel NO-Independent Guanylyl Cyclase Stimulator, BAY 41-8543: <i>in vitro</i> Studies. (2002) <i>Br J Pharmacol</i> 135 (2), 333-43	
	AM	Stasch, J., et al., NO and Haem Independent Activation of Soluble Guanylyl Cyclase: Molecular Basis and Cardiovascular Implications of a New Pharmacological Principle. <i>British J of Pharmacology</i> (2002) Vol. 136, No. 5, pp. 773-783	
	AN	Stone, J. R., et al., Spectral and Ligand-Binding Properties of an Unusual Hemoprotein, the Ferric Form of Soluble Guanylate Cyclase. <i>Biochemistry</i> (1996), 35, 3258-62	
	AO	Sunahara, R. K., et al., Exchange of Substrate and Inhibitor Specificities between Adenylyl and Guanylyl Cyclases. (1998) <i>J Biol Chem</i> . 273 (26), 16332-8	
	AP	Takahashi, M., et al., Cyclic GMP Production by ANP, BNP, and NO During Worsening and Improvement of Chronic Heart Failure. <i>Jpn Heart J</i> , 2003. 44(5): p. 713-24	
	AQ	Tomita, T., et al., Effects of GTP on Bound Nitric Oxide of Soluble Guanylate Cyclase Probed by Resonance Raman Spectroscopy. (1997) <i>Biochemistry</i> 36 (33), 10155-60	
	AR	Wedel, B., et al., Functional Domains of Soluble Guanylyl Cyclase. (1995) <i>J Biol Chem</i> 270 (42), 24871-5	
	AS	Zhao, Y., and Marietta, M. A., Localization of the Heme Binding Region in Soluble Guanylate Cyclase. (1997) <i>Biochemistry</i> 36 (50), 15959-64	
	AT	Zhao, Y., et al., Identification of Histidine 105 is the β 1 Subunit of Soluble Guanylate Cyclase as the Heme Proximal Ligand. (1998) <i>Biochemistry</i> 37 (13), 4502-9	
	AU	Zhao, Y., et al., A Molecular Basis for Nitric Oxide Sensing by Soluble Guanylate Cyclase. (1999) <i>Proc Nat'l Acad Sci USA</i> 96 (26), 14753-8	
	AV	PCT/US04/03853, PCT International Search Report dated October 28, 2004	

Examiner Signature	RG GIRON	Date Considered	7/24/06
--------------------	----------	-----------------	---------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. Send To Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2